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1. Introduction 
Chagas’ disease is an infection caused by the parasite Trypanosoma cruzi, mainly occurring in 
American countries where the parasite vector bug, Triatoma infestans, is widespread. One 
hundred million individuals are currently under threaten of infection, as well as 16 million 
people are considered affected by the illness in Latin America alone.(Editorial, 2009) 
Considering indicators such as the disability-adjusted life years, DALY, and from a social 
point of view, Chagas’ disease accounts for the third most important tropical illness of the 
World, following malaria and schistosomiasis.(Bitran et al., 2009) Moreover, Chagas disease 
epidemiology nowadays impacts in non-endemic regions due to globalization, being the 
infection disseminated all over the world (Gascon et al. 2009). Certainly, the non-vectorial 
disease transmission (mother to child, transfusional and by organ transplantation) is the 
way the illness spreads in Europe, North America, Japan, and Australia, because many 
infected people have migrated from endemic regions to distant cities. (Bowling & Walter, 
2009; Lescure et al., 2009; Yadon & Schmunis, 2009)  
The parasite distribution and living habits of rural Latin-American people have 
determined that the main transmission route is the vectorial one (via Triatoma infestans), 
leading to up 80% of human infection.(WHO, 2003) The main contagion way in urban 
areas arise from blood-transfusion, being responsible for 5-20% of the reported cases, 
while vertical transmission (mother-to-child) accounts for  2-10% of the infections.(Carlier 
& Torrico, 2003) 
The infection transmission by oral route because of consumption of contaminated food and 
drinks is lower than that reported for the previously-mentioned routes.(Dias et al., 2011) 
However, it has to be taken into account that the success of the non-oral infection prevention 
has increased the importance of the oral route of transmission.(Dias et al., 2011; Nóbrega et 
al., 2009) It is noteworthy that the acute outcome of the oral infection is particularly 
severe.(Bastos et al 2010). 
From the clinical point of view, the illness presents variable unspecific symptoms, 
depending on its stage: the acute one, shortly after primary infection, and the chronic stage, 
which may last many years if the individual is not treated. Human infection typically 
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appears with an incubation period of 4-10 days, which is generally asymptomatic. 
Afterwards, the infection may advance to the short acute phase, followed by the long-lasting 
chronic stage, which may occur in a syntomatic or asymptomatic way.  
The acute stage of the infection usually lasts 2-4 months. When symptoms appear, these are 
often light and atypical. The infection proceeds generally unnoticed, and this prevents its 
diagnosis. Most of the patients recover within 3-5 months. However, global mortality during 
this phase reaches 5-10%,(WHO, 2002) and may be higher in children.(Pinto et al., 2004) Deaths 
can be caused by complications related to myocarditis and/or meningoencephalitis,(Pittella, 
2009) which has been proved by the presence of the amastigote form of parasites in cardiac, 
skeletal, glial and soft tissue cells.(da Silveira et al., 2007)  
The undetermined, chronic phase generally begins 8-10 weeks after the acute infection, 
and may last several years or even the whole life of the individual. The illness overtakes 
asymptomatically, and generally, infected individuals keep their full working capacity 
without being aware of the infection. However, during this stage, patients display 
positive serology for specific IgG antibodies and low parasitemia.(Coura, 2007) Over 50% 
of the infected individuals show themselves healthy and do not develop serious 
outcomes. In the other cases, the infection is often detected once its sequels appear, after 
10-20 years of the first parasite entry. The illness features that mainly develop are cardiac, 
digestive and/or neurological damages. Chagas’ pathologic alterations can be 
summarized as chronic myocarditis, 27%, esophageal or colonic expansion, 5%, and 
abnormalities of central nervous system, ca. 3%.(Teixeira et al., 2006) The most severe 
impact of the illness occurs during chronic phase, and after many years that the infection 
has been established, leading to high mortality rate among people who have develop 
cardiac pathology.(Rassi, Jr. et al., 2007)  
Undoubtedly, the most effective alternative to prevent Chagas’ disease spreading is to 
control vectorial and transfusional ways of transmissions. Nevertheless, once the 
individual has been infected by T. cruzi, he/she may be treated. Two main aspects are 
covered by therapy, aiming to eliminate the parasite with trypanocidal medication, 
and/or medicating to relief symptoms of the several clinical outlines of the illness. 
Nowadays, two chemicals are used as trypanocidal agents namely, nifurtimox (Lampit®, 
Bayer; 5-nitrofuran 3-methyl-4-(5’-nitrofurfurylideneamine) tetrahydro-4H-1,4-tiazine-1,1-
dioxide) and benznidazole (Rochagan® and Radanil®, Roche; N-benzyl-2-nitroimidazole 
acetamide). When infection is treated during the acute stage, it has been reported that 
parasitemia disappeared in 60% of the cases and serology turned into negative. 
Nevertheless, the outcome after therapy is finished shows variable effectiveness 
percentages, depending mainly on the age of the individual and the geographical 
region.(Perez-Molina et al., 2009) 
Currently, studies trying to expand the indicators on treatment effectiveness are in progress 
and will be accomplished by 2012.(Marin-Neto et al., 2008) Though these studies have not 
yet finished, there is a consensus on treating Chagas’ disease, taking into account the clear-
cut results when using trypanocidal medication with children, during the indeterminate 
phase of the infection.(Lescure et al., 2010;Perez-Molina et al., 2009;Sosa-Estani & Segura, 
2006) It therefore follows that it is highly advisable to count with reliable methods to early 
diagnose the disease, since this may accelerate the patient treatment, helping to reduce the 
serious consequences that the long term infection may cause.  
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1.1 T. cruzi infection diagnostic during the different stages of the illness  
The infection diagnosis is not a simple task because the features of the illness development 
as well as the immunological response of the host must be taken into account when 
performing the laboratory diagnosis. Different diagnostic methods are used, depending on 
the illness stage and the particular clinical entity of the patient. 
The alternative ways to get acute Chagas’ infection are mainly vectorial and vertical 
transmission, and the reactivation of the chronic disease in immunosuppressed individuals. 
Therefore, diagnosis at this stage limits to: i) the uncommon cases of symptomatic patients, 
ii) newborns delivered from chagasic mothers, and iii) immunosuppressed patients that 
have been previously diagnosed as infected.  
In the above mentioned cases, parasites are usually, easily found in blood, therefore being 
their direct microscopic observation the chosen method for a safe diagnosis.(WHO, 
2002;Rosenblatt, 2009) In contrast, indirect serological techniques present low sensitivity in 
recently infected individuals because humoral immune response is delayed.(Zuniga et al., 
2000) Moreover, even specific IgM immunoglobulin has a window period that requires up 
to several weeks to be produced at detectable concentrations. Other pitfalls such as the lack 
of IgM anti-T. cruzi commercial kits prevents from choosing serology as the infection 
diagnostic method. This methodology is only used when the parasite is not found in fresh 
blood smears, by Struot and/or microhematocrit methods.(Luquetti & Schmunis, 2010)  
During the chronic phase, the T. cruzi infection diagnosis is required, i) as pregnancy or 
occupational routine control analysis -in countries where according legislation is in force-, ii) 
when in presence of a Chagas’ compatible cardiopathy, iii) during transfusion and 
transplantation screening, and iv) to achieve a reliable illness prognosis of patients who 
were already diagnosed. One particular case among the latter ones is monitoring the 
antiparasitic treatment effectiveness.  
Conversely to what happens in the acute phase, during the chronic infection, a significant 
humoral response is found in immunocompetent individuals, along with low parasite 
concentration in blood. Under these circumstances, indirect techniques are highly sensitive, 
while the direct ones fail. Hence, Chagas’ disease serologic diagnoses intend to verify the 
occurrence of several specific antibodies against T. cruzi. However, conventional serology 
presents different sensitivity and selectivity, depending on the immunological technique 
used to perform the determination, and mainly in the nature of the antigen used to capture 
the specific antibodies.(Belluzo et al., 2011) 
In this Chapter, we will describe the most recent contributions of our and other groups to 
improve the analytical tools available to properly and safely diagnose Chagas’ disease using 
recombinant proteins, in each one of the clinical entities mentioned above. 
2. Conventional diagnosis of T. cruzi infection  
Direct parasite detection in whole blood is the simplest, regular procedure used to diagnose 
acute infection whereas, indirect serological tests are the chosen ones to diagnose the 
undetermined, chronic state.(Rosenblatt, 2009;WHO, 2002)  
2.1 Parasitological and serological diagnosis of acute entities 
The direct microscopic observation of parasites from patients peripheral blood is the elected 
methodology to confirm acute infection. The Strout concentration method is the routinely 
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performed parasitologic analysis in adults since more than 50 years,(Strout, 1962) and it has 
been reported about 95% sensitivity.(Freilij & Storino, 1994)  
The other commonly used concentration method is the pediatric, more recent version, 
named the direct micromethod or microhematocrit, which requires a lower blood volume 
than Strout method, and is mainly used to diagnose congenital Chagas’ disease and acute 
infection in children.(Freilij et al., 1983;Freilij & Altcheh, 1995) However, newborn babies 
usually present low parasitemia, therefore making difficult to perform a proper 
conventional parasitologic analysis. It is then recommended to perform serologic tests to 
diagnose the congenital infection. The evaluation of specific anti-T. cruzi IgA and IgM is not 
recommended due to the high rate of false-negative results in neonates.(Moya et al., 2005) 
Considering that maternal specific anti-T. cruzi IgG antibodies are commonly present in 
newborn circulating blood, even up to the ninth month, it is not advisable to perform 
serologic IgG determinations as routine, in newborns younger than 9 months old. In this 
line, if the micromethod is negative or if it has not been performed during the first months 
of life of the newborn, then congenital infection should be serologically diagnosed using 
peripheral blood not before the child is 9 months old, once maternal antibodies have 
disappeared.(Gomes et al., 2009) Following, when specific IgG presence is negative after the 
ninth month of life, then vertical transmission is ruled out. Alternatively, during the first 
months of life of babies, it is possible to forego results using other non-standard, more 
expensive techniques such as the polymerase chain reaction, PCR.(Diez et al., 2008) This 
technology is particularly preferred when the health center counts with the supplies to carry 
out the methodology. 
Indirect parasitological methods are also used, mainly when the parasite is not easily found 
in samples. These methods are the hemoculture and xenodiagnosis, and consist of enriching 
the parasites present in the patient’s blood sample, through allowing their 
replication.(Chiari et al., 1989) Both of these latter techniques are also used when diagnosing 
chronic infection. These methods demand long periods of time to arise to the results (weeks 
or months), together with other drawbacks. For example, xenodiagnostic method has the 
disadvantage of producing rather variable sensitivity results, 20-50%, alongside the 
requirement of a suitable building infrastructure and trained personnel to deal with insect 
breeding. Thus, this method is not commonly performed in basic health centers.(Luquetti & 
Schmunis, 2010) 
When searching for reappearance of acute infection in immunosuppressed individuals 
under risk, negative serological results are not always associated with absence of the 
infection. This is a consequence of the immunological status of the patient that shows 
difficulties to produce detectable amounts of specific IgG. As mentioned previously, in the 
particular, difficult cases, expensive PCR techniques are the recommended diagnostic 
method. 
2.2 Serological diagnosis of chronic entities 
The widely used serological assays to diagnose T. cruzi infection in present clinical practice 
are indirect haemagglutination (IHA), indirect immunofluorescence (IIF), and enzyme-
linked immunosorbent assay (ELISA).(WHO, 2002;Yadon & Schmunis, 2009) The analyst’s 
choice of the particular technique depends on sanitary-authority recommendations, market 
impositions, and the lab-technician preference. This latter one is generally related to the 
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methodology simplicity, and the personal confidence he/she has in a particular technique 
after having performed it for a long while. 
IHA is an inexpensive technique, which is easy to be performed and interpreted, and it has 
been used for more than 50 years, therefore being appropriately settled among lab 
technicians. Similarly, IIF was developed in the sixties and presents equivalent features to 
IHA though, more skillful technicians are required to perform the analysis and produce 
accurate readings, as well as it needs a fluorescence microscope. IIF is a very sensitive, 
specific and cheap alternative for those who have the equipment and the trained personnel. 
However, regular health centers do not count with both of them. 
ELISA is a more recent technique which was firstly described during 1975 to diagnose 
Chagas’ disease,(Voller et al., 1975) and its usage was settled just at the ends of the eighties. 
This technique has the advantage of being widely extended as a diagnostic tool of many 
infections. Therefore, most of regular laboratories have the required equipment and trained 
personnel to appropriately perform the analysis. Contrarily to IHA and IIF, ELISA may be 
performed with automatic equipment at large health institutions. Moreover, even though 
ELISA is more expensive than the other two techniques, its notable performance in terms of 
sensitivity and specificity, has made of this the preferred methodology to diagnose T. cruzi 
infection.(Saez-Alquezar et al., 1997) 
Recently, one very fast technique with a different format has been developed namely, lateral 
chromatography.(Ponce et al., 2005;Barfield et al., 2011) This methodology uses small volume 
samples such as one serum drop, and allows acquiring results in 15 min, therefore being 
useful to perform the test in the field, without the need of refrigerator to preserve the 
reagents. Several multicenter studies have demonstrated that a commercial lateral 
chromatography kit show more than 92% sensitivity, whereas specificity is ca. 96%.(Ponce et 
al., 2005;Brutus et al., 2008;Roddy et al., 2008;Sosa-Estani et al., 2008) 
The fundamental problems of T. cruzi infection serological diagnostic methods are the lack 
of reproducibility that sometimes occur, deficient immunological reaction specificity, what 
produces false-positive results, and the occasional insufficient sensitivity translated into 
false-negative outcomes.  
Chagasic infection serology tests may produce cross-reactions with antibodies produced 
during the course of other illnesses. In this line, unspecific reactivity has been described for 
infections caused by T. cruzi phylogenetically related microorganisms, such as T. rangeli and 
Leishmania sp.(Soto et al., 1996;Araujo, 1986;Saez-Alquezar et al., 2000) Moreover, other false-
positive results due to cross-reactions have been described when testing samples from 
patients with autoimmune diseases,(Reiche et al., 1996) or from individuals suffering from 
other acute infections or pregnant women who display an important, polyclonal unspecific 
response.(Konishi, 1993) 
The clinical practice often finds an important number of inconsistent results regarding 
reproducibility and confidence when diagnosing chagasic infection. The lack of reproducibility 
and confident results has also been reported in a multicenter study.(Saez-Alquezar et al., 1997) 
In this work, it was proved the deficiency of reagents standardization, what produced 
incongruent results when testing the same serum panel. Along the same direction, since the 
early nineties, several works accounted for the huge losses caused by disposal of whole blood 
reservoirs typified as undetermined for T. cruzi infection.(Carvalho et al., 1993;Salles et al., 
1996;Saez-Alquezar et al., 2000) Taking into account tests discrepancies, one of WHO 
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recommendations states that T. cruzi infection must be diagnosed when the sample produces 
positive results by two different serological methods, whereas the undetermined condition is 
established for samples rendering dissimilar outcomes. 
Traditionally, whole parasites, or extracts from laboratory strains of T. cruzi epimastigotes 
cultures, have been the source of antigens used for the serological infection diagnosis. 
However, this yields to complex protein mixtures of unknown composition, which display 
severe difficulties to be standardized, and additionally lead to false-positive results. 
The diagnostic problems arising from serology deficient specificity, as well as the deprived 
reagents standardization, can be resolved through the use of defined antigens, such as the 
proteins obtained by molecular biology technology procedures.(Saez-Alquezar et al., 
2000;Umezawa et al., 2003;Umezawa et al., 2004;Aguirre et al., 2006) 
The following sections will be focused in this issue and the most important contributions 
that several research groups have recently made. 
3. Use and prospects of recombinant DNA technology  
Since the emergence of recombinant DNA technology, many protein molecules have been 
designed and prepared to eventually be assessed for serological diagnosis. The proteins 
obtained through this technology may be used as antigens to capture antibodies, to evaluate 
exclusively defined molecules, avoiding potential interferences from other components that 
usually occur when the antigens have been obtained by purifying native source proteins. 
(da Silveira et al., 2001) It follows that the usage of recombinant proteins as antigens to 
detect or quantify specific antibodies markers of a disease permits enhancing the specificity 
of the immunological reaction involved, therefore leading to more accurate 
diagnosis.(Aguirre et al., 2006;Camussone et al., 2009) 
In this methodology the proteins are usually prepared by heterologous expression, mainly in 
Escherichia coli cells.(da Silveira et al., 2001) Sequences of T. cruzi-protein codifying-DNA are 
inserted in a bacterial plasmid, which is transformed in competent bacteria. The proteins 
encoded by the plasmid are expressed in the bacterial culture, and are afterward purified into 
a highly pure product. The advantage of the proteins thus obtained is that they are an entirely 
characterized antigen, which may be evaluated individually for antibody determination in 
different clinical conditions. The prepared antigens can therefore be characterized considering 
the clinical information they provide, and may then be used to prepare specific diagnostic 
reagents. These proteins count with one desired feature of diagnostic reagents, as it is that their 
production and evaluation can be highly standardized. From another point of view, 
recombinant antigens do not require manipulation of the infective agent as do the antigens 
obtained by purification procedures from rough cultures. This has been a significant progress 
when considering the characteristics of viral infective agents, for which reagents production 
has substantially switched to that derived from recombinant DNA technology. Not less 
important is the major saving financial benefit of these reagents. Indeed, once bacteria are 
transformed into competent, protein producing strain, they can be used to prepare substantial 
amounts of antigen with low cost of production. 
Using this technology, many gene expression clones have been create, a fact that has made 
available the obtainment of massive amounts of highly pure, standardized T. cruzi 
proteins.(da Silveira et al., 2001) 
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During the latest three decades, many parasite antigens have been cloned and characterized. 
The cloned antigens correspond to different parasite stages namely, the trypomastigote 
sanguineous, the amastigote intracellular and the epimastigote, which is the form found 
inside the vector bowel and that can be cultured. Several of these antigens were obtained by 
immunological tracing through expression of cDNA libraries from chagasic patient sera, as 
well as from immunized animals.(Lafaille et al., 1989;Affranchino et al., 1989;Levin et al., 
1989;Cotrim et al., 1990;Gruber & Zingales, 1993) The antigen codifying genes have been 
identified from cDNA present in the libraries accomplished from epimastigote or 
trypomastigote forms.(Affranchino et al., 1989;Levin et al., 1989;Gruber & Zingales, 
1993;Godsel et al., 1995) Lately, Da Rocha et al. have proposed using amastigote proteins 
since this is the intracellular parasite form, being these antigens more significant for 
serodiagnosis.(DaRocha et al., 2002) 
The usage of DNA technology brought into light the existence of many parasite antigens 
with repetitive sequences, a fact that had been previously described when cloning proteins 
of other parasites.(Hoft et al., 1989) Generally, these are the most immunogenic antigens, and 
are the mainly selected when performing immunological tracing in cDNA libraries cloned in 
phages. Therefore, it was initially stated that these were the most valuable antigens for 
diagnosis.(Frasch & Reyes, 1990) However, it was afterward proved that some non-
repetitive antigens have equivalent diagnostic value than repetitive ones. Certainly, a 
multicenter study evaluated in parallel 4 repetitive recombinants antigens (H49, JL7, B13, 
JL8) together with 2 non-repetitive ones (A13 y 1F8).(Umezawa et al., 1999) The results 
demonstrated that both type of antigens were similarly useful for T. cruzi infection 
diagnosis, and the authors suggested that if they were to be used together in a mixture, they 
could supplemented each other enhancing the sensitivity of the assay. This was afterwards 
proved by the same group, see Tables 1 A,B and C.(Umezawa et al., 2003) 
Once the complete genome sequence of Trypanosoma cruzi was annotated, (El Sayed et al., 
2005) alternative antigenic candidates have been searched in the parasite genome. The 
studies have been supported by bioinformatic prediction of putative proteins and 
antigenicity predictors.(Goto et al., 2008;Cooley et al., 2008;Hernandez et al., 2010) Using 
these tools, it has been possible to choose antigens which display the lowest homology level 
with proteins of organisms related to T. cruzi.(Hernandez et al., 2010) Moreover, the 
bioinformatic analysis has allowed describing for the first time a specific antigen to type 
discrete typing units (DTUs). (Di Noia et al., 2002) 
The results published by many different laboratories point towards considering 
recombinant proteins as the chosen molecules to be used in immunoassays to diagnose T. 
cruzi infection. Moreover, the lack of specificity leading to false-positive results can be 
overcome by deleting sequence regions encoding for proteins which cross-react when 
analyzing negative sera,(Aguirre et al., 2006), or using recombinant proteins that are specific 
for anti-T. cruzi antibodies, yet keeping a high sensitivity.(Belluzo et al., 2011;Camussone et 
al., 2009) Indeed, the largest studies on the diagnosis reveal the convenience of using these 
antigens, regarding not only specificity but also the possibility of standardizing both, the 
methodology and the protein production.(Umezawa et al., 1999;Saez-Alquezar et al., 
2000;Umezawa et al., 2003) 
The following table display the key recombinant antigens discussed in the present 
chapter, which were evaluated by several authors for T. cruzi infection diagnosis. Notice, 
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that many of these antigens particularly named by one author have amino acid sequences, 
which may be very similar to those obtained by other authors who have named them 
differently (e.g. FRA, Ag1, JL7, H49). Identical or highly similar antigens were grouped in 
the same row. 
 
 
 
Antigen 
(grouped by 
high identity) 
Characteristics Diagnostic use Described by 
CRA 
Ag30 
JL8 
TCR27 
RP4 
Cytoplasmic 
antigen 
Chronic infection Lafaille et al., 1989 
Ibáñez et al., 1988  
Levin et al., 1989 
Hoft et al., 1989 
Camussone et al., 2009 
FRA 
Ag1 
JL7 
H49 
RP1 
Cytoskeleton 
associated protein
Chronic infection Lafaille et al., 1989 
Ibañez et al., 1988 
Levin et al., 1989 
Cotrim et al., 1995 
Camussone et al., 2009 
B13 
Ag2 
TCR39 
PEP-2 
RP5 
Trypomastigote 
surface protein  
Chronic infection Gruber et al., 1993 
Ibañez et al., 1988 
Hoft et al., 1989 
Peralta et al., 1994 
Camussone et al., 2009 
Ag36 
 
JL9 
MAP-like 
RP3 
 
Microtubule 
associated protein
Chronic and acute 
infection.  
Antibodies against this 
protein render cross-
reactions with mammal 
cell cytoskeleton.  
Ibañez et al., 1988 
 
Levin et al., 1989 
Kerner et al., 1991 
Camussone et al., 2009 
 
 
 
 
Table 1A. Relevant repetitive recombinant antigens proposed for diagnostic uses. 
Abbreviations used: CRA, cytoplasmic repetitive antigen; FRA, flagellar repetitive antigen; 
MAP, microtubule associated protein. RP1, RP3, RP4 and RP5, repetitive peptide 1, 3, 4 and 
5, respectively. 
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Antigen name Characteristics Diagnostic use Described by 
SAPA 
 
 
 
 
 
RP2 
Trans-sialidase 
family 
 
Acute and congenital 
infections.  
 
Chronic infection in 
leishmaniasis endemic 
regions 
 
Frasch & Reyes, 1990 
Russomando et al., 
2010 
Breniere et al., 1997 
Gil et al., 2011 
Camussone et al., 
2009 
TcLo1.2 Trans-sialidase 
family 
Chronic infection Houghton et al., 1999 
TcD Trans-sialidase family Chronic and acute infection Burns, Jr. et al., 1992 
Trans-sialidase 
catalytic region 
Trans-sialidase 
family 
Confirmation of chronic 
infection 
Buchovsky et al., 2001 
FL-160 
 
CEA 
 
CRP160 
Complement 
regulatory protein 
from TS-like family
Chronic infection and cure 
monitoring 
Chronic infection and cure 
monitoring 
Cure monitoring 
Cetron et al., 1992 
 
Jazin et al., 1995 
 
Meira et al., 2004 
TSSAI Trypomastigote 
muscin of TS-like 
family 
T. cruzi typing  
(named lineage Tc I, in the 
previous nomenclature) 
Di Noia et al., 2002 
TSSAII 
  
  
Trypomastigote 
muscin of TS-like 
family  
  
T. cruzi typing (named 
lineage Tc II, in the 
previous nomenclature) 
DTUII, V and VI in the 
current nomenclature 
Confirmatory diagnostic in 
Chagas and leishmaniasis 
co-endemic regions 
Di Noia et al., 2002 
 
Bhattacharyya et al., 
2010 
 
Cimino et al., 2011 
 
Table 1B. Relevant recombinant antigens which belong to tran-sialidase (TS) and TS-like 
family, proposed for diagnostic uses. Abbreviations used: CEA, chronic exoantigen (160 
KDa); CRP, complement regulatory protein; FL-160, surface flagellar protein (160 KDa); RP2, 
repetitive peptide 2; SAPA, shed-acute phase antigen. 
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Antigen name Characteristics Diagnostic use Described by 
R13 
 
 
P2β 
 
Last 13 amino acids 
from ribosomal 
protein. 
Full length ribosomal 
P2β protein 
Specific of cardiac disease 
 
Stages of cardiac disease 
Stages of cardiac disease 
All stages 
Aznar et al., 1995 
 
Diez et al., 2006 
Fabbro et al., 2011 
Breniere et al., 2002 
TcE Ribosomal protein Chronic infection Houghton et al., 1999 
FcaBP 
1F8 
Tc-24 
F29 
Tc-29 
Calflagin 
Flagellar calcium 
binding protein  
Chronic and acute infection
Chronic infection 
Cure monitoring patients 
Cure monitoring patients 
Chronic infection 
Chronic infection 
Engman et al., 1989 
Gonzalez et al., 1985 
Krautz et al., 1995 
Fabbro et al., 2007 
Abate et al., 1993 
Marcipar et al., 2005 
cy-hsp70 
mt-hsp70 
grp-hsp78 
Heat Shock Proteins Chronic infection and cure 
monitoring 
Krautz et al., 1998 
TcAg29 Alginate regulatory 
protein 
Chronic infection DaRocha et al., 2002 
TcAg48 RNA binding protein Chronic infection DaRocha et al., 2002 
Tc1 Repetitive proteins 
obtained by 
bioinformatic analysis 
of the genome 
Chronic infection Goto et al., 2008 
Tc3 Idem Chronic infection Goto et al., 2008 
Tc4 Idem Chronic infection Goto et al., 2008 
Tc9 Idem Chronic infection Goto et al., 2008 
Tc10 Idem Chronic infection Goto et al., 2008 
Tc12 Idem Chronic infection Goto et al., 2008 
Tc15 Idem Chronic infection Goto et al., 2008 
 
Table 1C. Other relevant recombinant antigens proposed for diagnostic uses. Abbreviations 
used: cy-hsp70, cytoplasmic thermal-shock protein; FCaBP, flagellar calcium-binding 
protein; grp.hsp 78, endoplasmic reticule thermal-shock protein (78 KDa); mt-hsp 70, 
thermal-shock mitochondrial protein (70 KDA). 
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4. Recombinant proteins use: Mixtures vs. fusion proteins  
The first works dealing with a single recombinant protein for diagnostic purposes reported 
lack of sensitivity when using only one of those antigens.(Levin et al., 1991;Moncayo & 
Luquetti, 1990;Peralta et al., 1994) Consequently, most of these proteins have been evaluated 
not only alone and independently from others, but also together as part of mixtures or as 
fusion proteins, carrying several recombinant epitopes.(Umezawa et al., 1999;Umezawa et 
al., 2004;Camussone et al., 2009;Foti et al., 2009) Accordingly, a multicenter study evaluating 
6 recombinant proteins separately with a serum panel composed by sera from patients of 
several countries, described that using the set of results of the 6 proteins together had yield a 
sensitivity and specificity compatible with the reference assays.(Umezawa et al., 1999) Later, 
the same group evaluated the mixture of the 6 proteins, supporting the use of the mixture to 
reach the same sensitivity and specificity.(Umezawa et al., 2003) Soon after, the reactivity of 
individual antigens vs. antigen mixtures was systematically assessed by ELISA.(Umezawa et 
al., 2004) This study confirmed that the results obtained with recombinant protein mixtures 
led to higher media values of optical densities, ODs, than the results produced when using 
the individual recombinant proteins. Moreover, sera rendering low ODs when examined 
with individual recombinant proteins produced higher ODs outcomes when using the 
protein mixtures. Along with this, several commercial ELISA kits with recombinant protein 
mixtures display equivalent or even higher sensitivities and specificities than those 
produced by kits with total parasite homogenate.(Gadelha et al., 2003;Pirard et al., 
2005;Remesar et al., 2009;Caballero et al., 2007) These works have studied kits using Ag1, 
Ag2, Ag30, Ag13 together with Ag36 recombinant antigens (Chagatest Rec from Wiener lab, 
Argentina), and FRA and CRA recombinant antigens (Biomanguinhos, Friocruz, Brazil). 
However, another study reported that Chagatest Rec v3.0 (Wiener) displayed a rather low 
95% sensitivity.(Ramirez et al., 2009)  
One of the strategies proposed to enhance reagents production standardization is to obtain 
multiepitope molecules, designed as a unique construction by fusing several relevant 
diagnostic antigens.(Houghton et al., 1999;Aguirre et al., 2006;Camussone et al., 2009) It has 
recently been proved that when using these constructions, the ODs of sera with low 
reactivity increases, as well as it had been reported for mixtures.(Camussone et al., 2009) 
Moreover, by this approach the attachment of the antigen turned out to be homogenous and 
reproducible when using different surfaces such as ELISA plaques, latex particles or 
bioelectrodes.(Camussone et al., 2009;Gonzalez et al., 2010;Belluzo et al., 2011) It has been 
proposed that when there is only one molecule exposed to the surface, competition for the 
active sites is prevented, therefore resulting in a uniform attachment. Furthermore, 
sensitivity may be increased because a higher number of freely accessible epitopes are 
available to capture the antibodies present in samples, as depicted in Fig. 1.(Camussone et 
al., 2009)  
A few articles report on the use of this strategy to produce commercial ELISA kits which have 
demonstrated to be highly satisfying. One of these works, analyzes the performance of the TcF 
antigen, previously described by Houghton et al in 1999, with which the Biolab Merieux 
reagent was prepared.(Ferreira et al., 2001) In this case, the recombinant protein used bears the 
PEP2, TcD, TcE and TcLo1.2 peptides. Recently, Abbot Laboratories have presented a new kit 
which uses a 4-antigen multiepitope protein containing TcF, FP3 -built up with TcR27 and 
FcaBP-, FP6 –with TcR39 and FRA- and FP10 -with SAPA and MAP-.(Praast et al., 2011) 
According to the authors, this kit performed even better than the Biolab Merieux one. 
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Fig. 1. Illustration of the ELISA plaque sensitizing process and the exposure to the sample: 
left-hand side, when using a protein mixture of three recombinant peptides RP1+RP2+RP5; 
right-hand side, when using a multiepitope chimeric protein bearing the same peptides 
fused in a single protein, CP2. RP: recombinant peptide, CP: chimeric protein obtained by 
fusion of peptides RP1, RP2 and RP5 together in only one molecule. Reproduction from 
Camussone et al 2009. 
5. Recombinant antigens use for the diagnosis of the different clinical 
entities 
5.1 Acute phase diagnosis  
As previously mentioned, during acute infection, serological methods are poorly sensitive. 
In the case of immunosuppressed individuals, as they do not develop an appropriate 
humoral immunological response, the direct method or molecular techniques are advisable. 
Serology is pertinent for in the neonatal congenital diagnostic when microhematocrit 
repeatedly shows negative results, or when diagnosis has not been made during the first 
month of life of the newborn. In these cases, it is necessary to serologically monitor 
congenital infection between 6 to 9 months, no matter if conventional reagents or 
recombinant ones are used.  
Nevertheless, the search for antibodies which are usually triggered during acute phase 
could enhance results. In the early nineties a shed acute phase antigen (SAPA) was 
proposed to discriminate between acute and chronic infection.(Reyes et al., 1990) This 
antigen was described when a panel of  recombinant proteins obtained from a cDNA library 
was used to analyze the reactivity of IgG antibodies occurring in sera of chronic chagasic 
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mothers and their newborns. The recognized IgGs against different T. cruzi antigens 
produced the same signal in sera from newborns and their respective mothers but SAPA 
antigen was recognized most frequently by antibodies from the infected newborns than it 
was by antibodies occurring in their mothers serum. Accordingly, the authors proposed it to 
be used to detect specific anti-T. cruzi IgG antibodies in neonates. Other works report that 
antibodies anti-SAPA allows the discrimination between acute and chronic T. cruzi infection 
because they were not present in the later stage of the infection.(Lorca et al., 1993) 
Nevertheless, later works described SAPA as reactive when assessed with sera from chronic 
infected individuals.(Breniere et al., 1997;Camussone et al., 2009) This apparent contradiction 
could be explained considering the significant differential reactivity of anti-SAPA antibodies 
generated during the different stages of the infection. Indeed, anti-SAPA antibodies are 
detected in almost all infected individuals but its reactivity is higher in the acute infection. It 
has recently been performed a study by following up of 2283 chagasic mothers, from which 
209 transmitted the infection to the newborns.(Russomando et al., 2010) This work provides 
evidence on SAPA utility to serologically diagnose congenital infection before the third 
month of life, thus turning the protein into a promising inexpensive reagent to reduce the 
required time to detect the neonatal infection, and proceed to its early treatment.  
Although different reactivity patterns have been described in Western Blot assays which use 
native T. cruzi excretion antigens, to discriminate between acute and chronic infection 
(Umezawa et al., 1996) no other useful recombinant antigen different from SAPA has been 
described to diagnose the acute phase. 
5.2 Chronic infection diagnosis 
It has been already mentioned above that, when T. cruzi homogenate is used to perform 
ELISA tests, the assay sensitivity is high leading to a quite reliable result, therefore some 
authors have suggested that a single assay could be enough to test sera in blood banks. (Sosa 
Stani et al., 2008;  Otani et al., 2009) 
Several multicenter studies carried out on samples from blood-banks, report that ELISA 
tests which use parasite homogenates perform similarly than those which used recombinant 
proteins.(Remesar et al., 2009; Otani et al., 2009) However, cross-reactivity of antibodies 
towards antigens from T. cruzi and Leishmania sp has been frequently informed, and can be 
explained considering the phylogenic proximity between both parasite species.(Chiller et al., 
1990;Vexenat et al., 1996;Chiaramonte et al., 1996;Desquesnes et al., 2007;Aguirre et al., 2006) 
When sera from patients infected with Leishmania ssp parasites are included in the 
evaluations, specificity of recombinant proteins are  higher (Umezawa et al.,  1999; Ferreira et 
al., 2001; Aguirre et al., 2006; Caballero et al., 2007; Camussone et al., 2009)  
It has been recently reported that the antigen TSSA2 displays 87.8% sensitivity and 100% 
specificity to discriminate between chagasic and leishmaniasic patients.(Cimino et al., 2011) 
TSSA2 is the only reported recombinant antigen, which has displayed specificity to type T. 
cruzi genotypes DTUII, DTUV or DTUVI by specific antibodies from infected patients. (di 
Noia et al., 2002; Bhattacharyya et al., 2010) As these DTUs are those predominant in South 
America, the authors proposed using this antigen in confirmatory T. cruzi infection 
diagnostic tests, in regions which are co-endemic for both infections. It was also described 
that SAPA antigen could be specific and sensitive enough to be used when trying to 
distinguish between chronic T. cruzi and leishmaniasic infections, in regions where both 
illnesses are co-endemic.(Gil et al., 2011) 
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It should be considered that it is difficult to discard T. cruzi infection in patients suffering 
from leishmaniasis, because these are co-endemic diseases. That is why antigens cross-
reactivity is normally assayed testing sera from patients who live in Chagas’ disease non-
endemic regions, because this allows ruling out T. cruzi infection from an epidemiological 
point of view. (Hernandez et al., 2010;Caballero et al., 2007;Aguirre et al., 2006)   It therefore 
follows the need to discuss and define new criteria to study the performance of 
immunochemical tests at those regions. In this regard, the enhanced sensitivity displayed by 
PCR techniques should allow overcoming the mentioned drawback.  
The lack of cross-reactions of T. cruzi recombinant proteins towards samples from T. rangeli 
infected individuals was also described. (Caballero et al., 2007) However, these are only 
preliminary results, and large evaluations have not been still performed since T. cruzi and T. 
rangelli are co-endemic and mixed infections are difficult to exclude with conventional or 
epidemiologic analysis. The first studies reporting discrimination of both infections using 
molecular approaches have been published in the last year and will allow to compose a 
serum panel with samples from patients suffering from either only one or both 
infections.(Botero et al., 2010) 
In spite of the advantages yielded when using recombinant antigens in ELISA, it has also been 
described that sensitivity varies according to the antigen used to sensitize plaques and the 
geographical region. Thus, sensitivity obtained when performing tests in Colombia using 
recombinant antigens related to the predominant strain in South America is different from that 
obtained when assays are carried out in regions at the South of the continent.(Ramirez et al., 
2009) The same holds true when examining samples from Panamá patients, where T. cruzi 
strains are very similar to those from Colombia. (Caballero et al., 2007) These works point out 
that serum level of antibodies in Panamanian patients were significantly lower than those from 
Brazilian individuals, from where the recombinant proteins were obtained using parasite 
genotypes isolated in Brazil. These data are in agreement with the serological differential 
reactivity produced by experimental infections in a mouse model, when strains representatives 
of different DTUs are inoculated.(dos Santos et al., 2009).  
5.3 Laboratory treatment monitoring  
The evaluation of treatment effectiveness is normally carried out through serological 
analysis. Direct parasitological techniques miss reliability because of the extremely low 
parasitemia, which after treatment diminishes more, even when total parasite elimination 
could have not been reached.  
Conventional serology turns into negative for more than 80% of the patients treated during 
the acute phase, once passed about 2 years after treatment. However, this percentage drops 
to less than 10% for patients who have been treated during the chronic phase, this taking 
several years.(Cancado, 1999) 
The patient status is classified, according to the laboratory tests results. Thus, patients are 
considered cured when parasitological tests and conventional serology are negative. When  
parasitological tests are negative and 2 of 3 conventional serological tests are positive, the 
patient is classified as dissociated. Patients are considered not to be cured when the 3 tests 
are positive.   
The serological test that demonstrated to be especially useful to monitor treatment 
effectiveness is the assessment of lytic antibodies. This test showed 100% correlation with 
parasitological cure, when lytic antibodies were evaluated in sera from patients who were 
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confirmed to be cured.(Krettli et al., 1979) The drawback of this test is the need to count with 
in vivo trypomastigotes culture, thus not being available in clinical diagnostic laboratories. 
Consequently, several recombinant antigens to evaluate patient’s treatment response have 
been proposed and assessed by ELISA as follows. 
The target antigen of lytic antibodies was identified as a 160 KDa molecule, a complement 
regulatory protein, usually named CRP.(Krettli, 2009) The assessment of antibodies against 
this protein displayed 100% correlation with that of lytic antibodies, when using both the 
native protein and the recombinant one.(Meira et al., 2004) 
Cruzipain and Tc24 are other recombinant proteins which were also evaluated to monitor 
patient’s treatment, and displayed 70% and 80% correlation with the lytic antibodies 
method, respectively.(Gazzinelli et al., 1993;Krautz et al., 1995) F29, which is Tc24 
homologous, was used to follow up the treatment in children younger than 12 years old, 
after 48 months of initiated the medication.(Sosa et al., 1998) This work reports that 67% of 
sera from treated children showed lack of anti-F29 antibodies whereas 100% of untreated 
children showed positive results for the specific antibodies. Therefore, the authors 
proposed to confirm the lack of anti-F29 antibodies as a serological marker of children 
cure. More recently, F29 was again evaluated as antigen of treatment monitoring in 
adults.(Fabbro et al., 2007) Results showed lack of the specific antibodies in 82.4% of sera 
from treated patients who still showed positive conventional serology. The same group 
has recently evaluated the levels of specific antibodies against the ribosomal protein 
TcP2β, as a cure marker. (Fabbro et al., 2011) Their results showed a significant decrease of 
specific anti-TcP2β in sera from treated patients, although no negative results occurred, 
which is a similar behavior than that displayed when performing conventional serology. 
Therefore, anti-TcP2β does not resemble to be an apparently good candidate to be used as 
an early marker of the infection cure. 
Another interesting study is the one where CRA and FRA antigens were evaluated, and 
displayed a 67% correlation with the reference technique. This makes CRA and FRA as quite 
promising antigens to be used for cure monitoring. The results are interesting considering 
that the Bio-manguinhos, Fiocruz commercial kit, commercialized in Brazil is manufactured 
with a single mixture of these two recombinant proteins.   
5.4 Chronic infection monitoring  
In the context of Chagas disease autoimmune hypothesis, during the nineties, it was 
proposed that different antigens contributed to the generation of autoantibodies, which 
could be used as illness evolution markers.(Leon & Engman, 2001) Among these antigens 
we should mention cruzipain, (Giordanengo et al., 2000;Goin et al., 1999;Duschak et al., 2001) 
sulfo-cerebrosides (Avila et al., 1993) and the ribosomal protein TcP2.(Levitus et al., 1991) 
Precursor works had described that this ribosomal antigen that shares the C terminal region 
with its homologous from humans, generated autoimmune antibodies, whose concentration 
was increased in patients who had developed chagasic cardiopathy.(Levin et al., 1991;Aznar 
et al., 1995). Our group evaluated the concentration of antibodies against cruzipain, sulfo-
cerebrosides and ribosomal TcP2 in three different groups of patients: those classified as 
asymptomatic, those who only displayed electrocardiographic alterations and those who 
had evident cardiopathy.(Diez et al., 2006) In our experience, only those samples from 
patients with evident cardiopathy had increased specific anti-TcP2 concentration. 
However, these results have not yet been confirmed analyzing a larger number of patients. 
In another study, anti-TcP2 concentration was higher in sera from patients at indeterminate 
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stage than in sera from symptomatic individuals.(Breniere et al., 2002) In a longitudinal 
evaluation of asymptomatic and cardiac groups of patients, we described that only the 
individuals who evolved to a more severe clinical status increased specific anti-TcP2 
concentration in late stages of the infection.(Fabbro et al., 2011) However, the transversal 
comparison of the sera from patients with and without cardiopathy revealed that anti-TcP2 
concentration between both groups was not significantly different. The discrepant results 
mentioned above show that it is not still clear  if anti-TcP2 can be used as a serological 
marker of myocardic damage. 
Also, muscarinic acetylcholine receptor subtype II, in this case a host antigen, has shown to 
be quite auspicious to monitor the chronic infection.(Goin et al., 1999) Nevertheless, recent 
studies suggest that it is not apparent that this protein is useful to discriminate between 
different stages of the illness.(Tovar et al., 2009;Talvani et al., 2006) 
The difficulties to establish clear illness evolution markers lead to the present state, where 
we do not count yet with useful tools to evaluate Chagas’ disease prognosis.    
6. Future prospects 
The number of recombinant proteins assessed and proposed as candidates to be used as 
tools for T. cruzi infection diagnosis is quite high. However, there is no serum panel to be 
used as international reference. Therefore, the reports on results produced by using these 
proteins can hardly be compared. Usually, serum panels, previously typified with other 
validated methods are used to appraise new serology reagents. These already standardized 
serological reagents have their own sensitivity and specificity, which may lead to a bias 
when typifying the panel.  
Currently, several diagnostic tests have been proposed as the reference one, such as 
immunofluorescence or different versions of Western blot.(Otani et al., 2009;Caballero et al., 
2007) However, no consensus exists among researchers and regulatory agencies on which 
tests are preferable.  
Another inconvenience is that there is evidence on the absence of humoral response in some 
patients of endemic regions, whose infection was proved by parasitological techniques or by 
tests evaluating the cellular immune response.(Salomone et al., 2003;Olivera et al., 2010) 
These reports alert us on a potential overestimation of the sensitivity and specificity 
underestimation of the immunochemical assays when they are assessed with serum panels 
typified by conventional serology. 
Conventional serology is still a crucial tool to diagnose the different entities studied during 
the chronic phase of the infection. The main multicenter studies carried out in regions where 
leishmaniasis is not endemic have shown that ELISAs using both parasite extractive 
antigens, as well as the recombinant ones, display optimal sensitivity and specificity.  
Although both kind of antigens perform similarly in those leishmaniasis-free places, when 
determinations are carried out where Chagas’ disease and leishmaniasis are co-endemic, 
ELISAs using recombinant proteins have demonstrated to be the most useful. 
In the same line, presently, several authors who have evaluated ELISA commercial kits with 
plaques sensitized with parasite homogenate or with recombinant antigens, have shown 
that it is not mandatory to carry out 2 different tests. Certainly, when performing only one 
ELISA, it is feasible to diagnose the infection, if the result is positive. This is acknowledged 
because results obtained with both kinds of ELISA correlate appropriately. (Remesar et al., 
2009;Otani et al., 2009) However, considering the poor sensitivity of IHA, this latter one 
would not be recommended as a second test. (Remesar et al., 2009) 
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Even though some recombinant proteins have been used to monitor Chagas´ disease 
treatment, it could not be still demonstrated that these proteins give diagnostic information 
to evaluate cardiopathy diagnosis and prognosis. During recent years, the description of the 
whole genome of T. cruzi has prompt to systematically analyze new antigens, some of which  
have been described as putative antigens, but has not yet confirmed. This is being evaluated 
nowadays by different research groups which, it is expected will suggest new interesting 
markers that are useful for cure monitoring and cardiopathy prognosis.  
Lately, several research works on infection diagnostic tools have reported on the 
development of latex particle agglutination and amperometric biosensors to diagnose T. 
cruzi infection.(Gonzalez et al., 2010;Belluzo et al., 2011;Ribone et al., 2006) Latex particle vs. 
conventional agglutination has the advantage of allowing particle sensitization with 
recombinant proteins, what leads to a more reproducible, standardized reagents 
production.(Gonzalez et al., 2010)  Biosensors technology admits reutilization of the device, 
potentially yielding to automation, thus facilitating laboratory operation. Moreover, the 
simplicity of the equipment required, permits the analysis to be performed in the field, 
which is an important attribute because infected people generally live in the countryside 
and do not attend health centers.(Belluzo et al., 2011) The electrochemical biosensor 
technology developed follows the same ELISA format, exchanging the colorimetric signal 
readout by the amperometric one.(Belluzo et al., 2011) Although no commercial device is yet 
available, the results of our studies are quite promising. This methodology could allow 
reducing costs and time of analysis in the near future, keeping the same or even higher 
standards of sensitivity and specificity than ELISA.(Belluzo et al., 2011) 
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